LitCovid-sample-Enju  

PMC:7199903 / 0-418 JSONTXT 19 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T0 0-13 JJ denotes Site-specific
T1 14-20 NN denotes glycan
T2 21-29 NN denotes analysis
T3 30-32 IN denotes of
T4 33-36 DT denotes the
T5 37-47 NN denotes SARS-CoV-2
T6 48-53 NN denotes spike
T7 55-65 NN denotes SARS-CoV-2
T8 66-71 NN denotes spike
T9 72-79 NN denotes protein
T10 79-80 -COMMA- denotes ,
T11 81-91 VBD denotes elaborated
T12 92-99 NN denotes Vaccine
T13 100-111 NN denotes development
T14 112-115 IN denotes for
T15 116-122 JJ denotes severe
T16 123-128 JJ denotes acute
T17 129-140 JJ denotes respiratory
T18 141-149 NN denotes syndrome
T19 150-161 NN denotes coronavirus
T20 162-163 CD denotes 2
T21 164-165 -LRB- denotes (
T22 165-175 NN denotes SARS-CoV-2
T23 175-176 -RRB- denotes )
T24 177-179 VBZ denotes is
T25 180-187 VBN denotes focused
T26 188-190 IN denotes on
T27 191-194 DT denotes the
T28 195-203 JJ denotes trimeric
T29 204-209 NN denotes spike
T30 210-217 NN denotes protein
T31 218-222 WDT denotes that
T32 223-232 VBZ denotes initiates
T33 233-242 NN denotes infection
T34 244-248 DT denotes Each
T35 249-257 NN denotes protomer
T36 258-260 IN denotes in
T37 261-264 DT denotes the
T38 265-273 JJ denotes trimeric
T39 274-279 NN denotes spike
T40 280-283 VBZ denotes has
T41 284-286 CD denotes 22
T42 287-300 NN denotes glycosylation
T43 301-306 NNS denotes sites
T44 308-311 WRB denotes How
T45 312-317 DT denotes these
T46 318-323 NNS denotes sites
T47 324-327 VBP denotes are
T48 328-340 VBN denotes glycosylated
T49 341-344 MD denotes may
T50 345-351 VB denotes affect
T51 352-357 WDT denotes which
T52 358-363 NNS denotes cells
T53 364-367 DT denotes the
T54 368-373 NN denotes virus
T55 374-377 MD denotes can
T56 378-384 VB denotes infect
T57 385-388 CC denotes and
T58 389-394 MD denotes could
T59 395-401 VB denotes shield
T60 402-406 DT denotes some
T61 407-415 NNS denotes epitopes
R0 T2 T0 arg1Of analysis,Site-specific
R1 T2 T1 arg1Of analysis,glycan
R10 T13 T12 arg1Of development,Vaccine
R11 T13 T14 arg1Of development,for
R12 T19 T14 arg2Of coronavirus,for
R13 T19 T15 arg1Of coronavirus,severe
R14 T19 T16 arg1Of coronavirus,acute
R15 T19 T17 arg1Of coronavirus,respiratory
R16 T19 T18 arg1Of coronavirus,syndrome
R17 T19 T20 arg1Of coronavirus,2
R18 T19 T21 arg1Of coronavirus,(
R19 T22 T21 arg2Of SARS-CoV-2,(
R2 T2 T3 arg1Of analysis,of
R20 T23 T21 arg3Of ),(
R21 T13 T24 arg1Of development,is
R22 T25 T24 arg2Of focused,is
R23 T13 T25 arg2Of development,focused
R24 T25 T26 arg1Of focused,on
R25 T30 T26 arg2Of protein,on
R26 T30 T27 arg1Of protein,the
R27 T30 T28 arg1Of protein,trimeric
R28 T30 T29 arg1Of protein,spike
R29 T30 T31 arg1Of protein,that
R3 T6 T3 arg2Of spike,of
R30 T30 T32 arg1Of protein,initiates
R31 T33 T32 arg2Of infection,initiates
R32 T35 T34 arg1Of protomer,Each
R33 T35 T36 arg1Of protomer,in
R34 T39 T36 arg2Of spike,in
R35 T39 T37 arg1Of spike,the
R36 T39 T38 arg1Of spike,trimeric
R37 T35 T40 arg1Of protomer,has
R38 T43 T40 arg2Of sites,has
R39 T43 T41 arg1Of sites,22
R4 T6 T4 arg1Of spike,the
R40 T43 T42 arg1Of sites,glycosylation
R41 T48 T44 arg1Of glycosylated,How
R42 T46 T45 arg1Of sites,these
R43 T46 T47 arg1Of sites,are
R44 T48 T47 arg2Of glycosylated,are
R45 T46 T48 arg2Of sites,glycosylated
R46 T44 T49 arg1Of How,may
R47 T50 T49 arg2Of affect,may
R48 T44 T50 arg1Of How,affect
R49 T51 T50 arg2Of which,affect
R5 T6 T5 arg1Of spike,SARS-CoV-2
R50 T52 T51 arg1Of cells,which
R51 T54 T53 arg1Of virus,the
R52 T54 T55 arg1Of virus,can
R53 T56 T55 arg2Of infect,can
R54 T54 T56 arg1Of virus,infect
R55 T52 T56 arg2Of cells,infect
R56 T50 T57 arg1Of affect,and
R57 T59 T57 arg2Of shield,and
R58 T44 T58 arg1Of How,could
R59 T59 T58 arg2Of shield,could
R6 T9 T7 arg1Of protein,SARS-CoV-2
R60 T44 T59 arg1Of How,shield
R61 T61 T59 arg2Of epitopes,shield
R62 T61 T60 arg1Of epitopes,some
R7 T9 T8 arg1Of protein,spike
R8 T11 T10 arg1Of elaborated,","
R9 T9 T11 arg1Of protein,elaborated